



Biocon Profile

Biocon: India's Largest Biopharma Focused on Affordable Innovation

Biocon, Asia's leading biotech enterprise, headquartered in Bangalore, India, is constantly engaged in delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage in order to provide access to affordable healthcare for patients, partners and healthcare systems across the globe.

As a fully integrated biopharma company Biocon delivers innovative solutions, across discovery, development and commercialization of biopharmaceuticals value chain, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, in order to move ideas to market.

Biocon, recognized as the largest Indian Insulins company, has several innovations to its credit, including world's first Pichia based recombinant human Insulin, INSUGEN[®], insulin analog Gargine, BASALOG[®], and India's first indigenously produced monoclonal antibody BioMAb-EGFR[®] for head & neck cancer. Biocon launched its second novel biologic, ALZUMAb[™], a 'first in class' anti-CD6 monoclonal antibody, for the treatment of chronic plaque psoriasis in India, in 2013. CANMAb[™], the trastuzumab for the treatment of HER2-positive metastatic breast cancer developed jointly by Biocon and Mylan under a global partnership, is being launched in India in 2014. INSUPen[®] based on German technology, is a next generation insulin delivery device introduced in India by Biocon.

The Company's aspiration to become a US \$ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, with a focus on emerging markets, these are Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services.



Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is constantly focused on innovation and is making rapid progress in its research and development programs across Biosimilars and Novel Biologics. Its robust novel and biosimilars pipeline focuses on diabetes, oncology and autoimmune diseases and has several molecules at different stages of the development cycle. Some of these key programs in advanced development are for recombinant human Insulin, which has successfully completed phase III EU clinical study, Glargine which has completed global phase I, and Trastuzumab which has entered global phase III. BVX 20, a novel molecule for blood cancer, has entered the clinics. The company is also committed to take ALZUMAb™, the world's first anti-CD6 novel biologic, to various markets across the globe for a wide range of autoimmune diseases and is actively looking for a partner.

Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 85 countries. Its Small Molecules business including statins, immunosuppressants and other proprietary molecules has been servicing customer needs across developed and emerging markets and the Company aims to further unlock value by front ending this business into ANDAs and 505 (b)(2) formulations. The Company's Branded Formulations business in India has been a strong growth driver and a considerable value builder for Brand Biocon in India. It has gained critical mass with a strong product portfolio of 80 brands and many of its products are in the top 5 in their respective categories. The Company is committed to achieving market leadership in its chosen therapeutic areas through a carefully orchestrated strategy of product differentiation and personalized medical support.

Biocon has also built a remarkable Research Services business through Syngene and Clinigene that offers integrated discovery and development solutions for both small and large molecules. It has partnered with over 100 global life sciences companies and has enabled them to address some of their innovation and productivity challenges through its services across discovery and development.

In order to address the global needs for biosimilar Insulins, the Company has expanded its footprint and is setting up Asia's largest integrated Insulins manufacturing and R&D facility in Malaysia, which will provide affordable therapy options to diabetes patients across multiple markets.

The Company remains committed to innovation and addressing the global challenges of affordability and access to healthcare, making a difference to the lives of patients it serves.

Through Biocon Foundation the Company is engaged in promoting social and economic inclusion by ensuring that marginalized communities have equal access to healthcare services and educational opportunities. The Company's initiatives are directed towards empowering the under-served communities through sustainable and affordable, healthcare & educational services.